Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial

Denosumab, a RANKL inhibitor, reduced the risk of vertebral, hip, and nonvertebral fractures in the Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) trial of postmenopausal women with osteoporosis compared with placebo. Previous bone histomorphometric analysis in F...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavassieux, Pascale, Portero‐Muzy, Nathalie, Roux, Jean Paul, Horlait, Stéphane, Dempster, David W, Wang, Andrea, Wagman, Rachel B, Chapurlat, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850394/
https://www.ncbi.nlm.nih.gov/pubmed/30601581
http://dx.doi.org/10.1002/jbmr.3631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850394/
https://www.ncbi.nlm.nih.gov/pubmed/30601581
http://dx.doi.org/10.1002/jbmr.3631

Ejemplares similares